Semaglutide injection for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Injection for Weight Loss: Efficacy and Patient Outcomes
Semaglutide Weight Loss Effectiveness in Adults with Obesity
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to produce significant and sustained weight loss in adults with obesity or overweight, especially when combined with lifestyle interventions such as diet and exercise. Clinical trials, including the STEP program, demonstrated that weekly injections of semaglutide 2.4 mg led to average weight reductions of 14.9% to 16.0% over 68 weeks, which is notably higher than the 4.0% to 10.9% weight loss seen with other anti-obesity medications 146. Real-world studies confirm these findings, with patients losing about 12% of their body weight after six months and up to 13.4% after twelve months of treatment 37.
Semaglutide for Patients with Type 2 Diabetes
In adults with both obesity and type 2 diabetes, semaglutide 2.4 mg once weekly resulted in a mean body weight reduction of 9.6% over 68 weeks, significantly outperforming placebo and lower doses of semaglutide . More patients on semaglutide achieved at least 5% weight loss compared to those on placebo, and improvements in blood sugar control were also observed 56.
Cardiometabolic and Health Benefits
Beyond weight loss, semaglutide treatment has been associated with improvements in metabolic health, including better lipid profiles, lower blood pressure, improved liver function, and reduced cardiovascular disease risk 27. These benefits make semaglutide a valuable option for patients with obesity-related health conditions.
Safety and Tolerability of Semaglutide
The safety profile of semaglutide is similar to other GLP-1RAs, with the most common side effects being mild to moderate gastrointestinal symptoms such as nausea and diarrhea 1456. While the overall incidence of adverse events is higher with semaglutide 2.4 mg compared to placebo, serious adverse events are less common, and most patients tolerate the medication well . Some patients may discontinue treatment due to side effects, but these cases are relatively infrequent .
Use in Children and Adolescents
Semaglutide has also been studied in children aged 10–18 years with obesity and weight-related comorbidities. After six months, children experienced an average weight loss of 6.4%, and after twelve months, the average was 8.9%. The medication was generally well tolerated, with mild gastrointestinal side effects being the most common .
Off-Label Use and Prescribing Trends
There has been a notable increase in the use of semaglutide for weight loss, including off-label prescribing in populations without type 2 diabetes. In Denmark, up to one-third of new semaglutide users in 2022 did not have diabetes, reflecting growing demand for its weight loss benefits .
Cost-Effectiveness
Economic analyses suggest that semaglutide 2.4 mg is a cost-effective option for weight management when used alongside diet and exercise, particularly in patients with obesity and related comorbidities . This supports its prioritization in clinical guidelines for long-term obesity treatment .
Conclusion
Semaglutide injection is a highly effective and generally well-tolerated treatment for weight loss in adults and children with obesity, with additional benefits for metabolic and cardiovascular health. Its use is supported by strong clinical evidence and real-world data, and it is considered cost-effective for long-term weight management. However, patients should be monitored for gastrointestinal side effects, and access may be limited by cost and supply issues.
Sources and full results
Most relevant research papers on this topic